ImmuPharma (LON:IMM) Stock Price Down 14.4% – Here’s Why

ImmuPharma plc (LON:IMM) dropped 14.4% on Monday . The company traded as low as GBX 8.33 ($0.11) and last traded at GBX 8.95 ($0.12). Approximately 12,629,833 shares changed hands during mid-day trading, an increase of 47% from the average daily volume of 8,586,172 shares. The stock had previously closed at GBX 10.45 ($0.14).

ImmuPharma Trading Down 14.4%

The stock has a market capitalization of £44.73 million, a price-to-earnings ratio of -1,005.62 and a beta of 1.53. The stock’s 50 day moving average is GBX 5.17 and its two-hundred day moving average is GBX 3.54.

ImmuPharma (LON:IMM) last announced its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, research analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.